Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "MIT"

5632 News Found

NATCO launches Everolimus tablets, 1 mg
News | October 31, 2025

NATCO launches Everolimus tablets, 1 mg

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation


Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
News | October 30, 2025

Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM

Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives


Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
News | October 30, 2025

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr

Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025


Granules India’s facility secures FDA EIR with 'VAI’
Drug Approval | October 30, 2025

Granules India’s facility secures FDA EIR with 'VAI’

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025


Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
News | October 30, 2025

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs


Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test
News | October 30, 2025

Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test

Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks


Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Clinical Trials | October 30, 2025

Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva


Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery
R&D | October 30, 2025

Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery

New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents